Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immune Response reports encouraging Remune HIV data
The study (IR101-215), conducted at four sites in Italy, was designed to explore the potential utility of Remune and ongoing analysis will explore immunological information. The findings focused
The study (IR101-215), conducted at four sites in Italy, was designed to explore the potential utility of Remune and ongoing analysis will explore immunological information. The findings focused
Trexima, developed in collaboration with GlaxoSmithKline, is the proposed brand name for the single tablet that combines sumatriptan and naproxen. The drug demonstrated superiority over its individual components
Patient enrollment for the study began in Canada in December 2004, with the first patients being dosed in January 2005. BioMS anticipates that 30 trial sites will ultimately
The drug, phentermine hydrochloride, is approved for the short-term management of obesity. Lannett expects to commence marketing the product in June 2005. Arthur Bedrosian, president of Lannett, was
This is the first time that a modifiable risk factor for MS progression has been identified, providing a new strategy for patients hoping to control neurological damage from
Patients three to 17 years of age with polyarticular-course rheumatoid arthritis were recruited to the study. The children were given either methotrexate (brand names include Stada Pharmaceuticals’ Rheumatrex
Protein Design Labs (PDL)’s wholly-owned subsidiary, ESP Pharma, has acquired from Orphan Therapeutics exclusive marketing, sales and distribution rights for terlipressin in the US and Canada. Orphan Therapeutics
The study will examine the safety, tolerability and efficacy of AVR118 in patients with advanced cancer who are suffering from symptoms of progressive disease, including weight loss, fatigue
Data presented at the American Association for Cancer Research (AACR) annual meeting in California showed that Tarvacin could be used to deliver a radioactive arsenic compound to prostate
The FDA’s decision was based, in part, on review of both phase I and phase II clinical trials of AP23573 conducted by Ariad in refractory sarcoma patients, and